



## **Aduro Biotech to Present at the 20th Annual H.C. Wainwright Global Investment Conference**

August 29, 2018

BERKELEY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 20th Annual H.C. Wainwright Global Investment Conference in New York, NY on Wednesday, September 5, 2018 at 1:45pm Eastern Time.

To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro's website at [www.aduro.com](http://www.aduro.com).

### **About Aduro**

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that are intended to transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, which may result in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 clinical trial as a single agent and in combination with ipilimumab and in a Phase 1b combination trial with spartalizumab (PDR001), an anti-PD1 immune checkpoint inhibitor. Aduro's B-select monoclonal antibody platform, including BION-1301, an anti-APRIL antibody, is comprised of a number of immune modulating assets in research and development. Aduro's pLADD program is based on proprietary attenuated strains of *Listeria* that have been engineered to express tumor neoantigens that are specific to an individual patient's tumor. Other *Listeria* strains for lung and prostate cancers are being advanced by a partner. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit [www.aduro.com](http://www.aduro.com).

### **Contact:**

**Jennifer Lew**  
**Chief Financial Officer**  
**510-809-4816**

### **Media Contact:**

**Aljanae Reynolds**  
**510-809-2452**  
[press@aduro.com](mailto:press@aduro.com)



Aduro Biotech, Inc.